Sun Pharma is set to nearly double its revenue to $12 billion with the acquisition of Organon, creating a global pharmaceutical giant. The deal leverages Organon’s strengths in women’s health, biosimilars, and established brands, aiming for significant growth despite geopolitical concerns. Integration plans and manageable debt are key to the strategic move.
The information on this website does not constitute investment advice or a recommendation or a solicitation to engage in any investment activity. This website and its content are not intended for residents of the UAE, US, Canada, Australia, UK, Russia, North Korea, China, Japan, Hong Kong, Singapore and Iran.
Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003